Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose study is to evaluate the efficacy and safety of Sorafenib as first line treatment
for patients - unsuitable for another approved first line therapy - with advanced RCC in the
Middle East Region.